A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.

Christoph KapitzaLeszek NosekWolfgang SchmiderLenore TeichertBhaswati MukherjeeIrene Nowotny

Published in: Diabetes, obesity & metabolism (2020)

SARAsp -Mix showed similar pharmacokinetic exposure to commercially available insulin aspart Mix 70/30 formulations, and a distinct exposure profile compared with SAR-Asp.

Keyphrases

type diabetes
glycemic control
insulin resistance
metabolic syndrome
skeletal muscle
quantum dots